Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01247558 · ClinicalTrials.gov registry record
Administrative Claims Analysis of Metanx® in Diabetic Peripheral Neuropathy
A clinical trial of Diabetic Peripheral Neuropathy (DPN), sponsored by Pamlab, L.L.C..
- Completed
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT01247558 is a study of Diabetic Peripheral Neuropathy (DPN) that has completed, run by Pamlab, L.L.C.. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01247558, a study of Diabetic Peripheral Neuropathy (DPN), has completed, sponsored by Pamlab, L.L.C..
- COMPLETED
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be an observational cohort study utilizing administrative claims data with 100 patients randomly selected taking Metanx® meeting the inclusion and exclusion criteria and 400 propensity score matched patients meeting the same criteria to serve as a control cohort for analyses. This data includes medical, and pharmacy claims from the HealthCore Integrated Research Database for claims submitted during the time period of 01/01/2002 through 06/30/2007.
Conditions Studied
Interventions
- OTHER Metanx® (a medical food)
- OTHER Not treated with Metanx®
Study Locations (1)
Delaware
- HealthCore, Inc. - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01247558
The ClinicalTrials.gov registry entry for NCT01247558 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pamlab, L.L.C., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Peripheral Neuropathy (DPN) appearing as the primary indexed condition, and to 2 interventions - of which Metanx® (a medical food) is the first listed.
NCT01247558 reports 1 study location spanning 1 distinct geographic area - top geographies include Delaware.
Frequently Asked Questions
What is clinical trial NCT01247558 about?
NCT01247558 is a clinical study titled "Administrative Claims Analysis of Metanx® in Diabetic Peripheral Neuropathy". This study will be an observational cohort study utilizing administrative claims data with 100 patients randomly selected taking Metanx® meeting the inclusion and exclusion criteria and 400 propensity score matched patients meeting the same criteria to serve as a control cohort for analyses. This da...
What is the current status of trial NCT01247558?
This trial is currently completed. The enrollment target is 500 participants. The study started on 2010-11. Estimated completion is 2011-09.
What conditions does trial NCT01247558 study?
This clinical trial studies the following conditions: Diabetic Peripheral Neuropathy (DPN).
What interventions are being tested in trial NCT01247558?
The interventions under investigation include: Metanx® (a medical food) (OTHER), Not treated with Metanx® (OTHER).
Who is sponsoring clinical trial NCT01247558?
This trial is sponsored by Pamlab, L.L.C., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01247558 being conducted?
This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.